Asthma Therapeutics Market In The Asia-Pacific Region Is Expected To Increase In Value At A CAGR Of 7.2%, To Become Over $5.6 Billion Till 2021

Researchmoz added Most up-to-date research on "Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns" to its huge collection of research reports.

Asthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact causes of asthma are currently unknown, and may be the result of a combination of factors, although two major factors thought to be involved are environmental exposure and host factors, particularly genes.

Asthma treatment can be classed as either a long-term control medication, aimed at controlling persistent asthma, or a quick-relief medication, for the relief of exacerbations and acute symptoms. Long-term control medication includes Inhaled Corticosteroids (ICS), immunomodulators, leukotriene modifiers, cromolyn sodium, nedocromil and methylxanthines. In addition, Long-Acting Beta-Adrenoceptor Agonists (LABAs) can be used in combination with ICSs – but not as monotherapies – for moderate or severe persistent asthma. Currently, only one biologic – Xolair (omalizumab) – is approved as an add-on therapy for the treatment of allergic asthma in the Asia-Pacific region.  Nevertheless, significant unmet need remains for the treatment of severe eosinophilic asthma.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=686317

Scope

The current asthma market in the Asia-Pacific region contains novel products, including Xolair, a recombinant humanized monoclonal anti-IgE antibody; Seretide/Adoair, an ICS-LABA combination therapy; Relvar/Breo, an ICS-LABA combination therapy, and Spiriva, a LAMA.

- What are the competitive advantages of the existing novel drugs?

With over 274 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, with improved dosing regimens and administration routes in comparison to currently marketed products.

- Which classes of novel drugs are most prominent within the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the asthma market – specifically for severe eosinophilic asthma?

Analysis of clinical trials since 2006 has identified that the failure rates of asthma molecules were highest in Phase III (46%), with the overall attrition rate for asthma in development being 78%.

- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?

Over the 2014–2021 forecast period, the asthma therapeutics market in the Asia-Pacific region is expected to increase in value at a Compound Annual Growth Rate (CAGR) of 7.2%, from $3.5 billion to over $5.6 billion.

- Which markets make the most significant contribution to the current market size?
- What are the epidemiology trends in these markets?
- Will new market entrants lead to substantial changes in annual therapy costs?
- How will different treatment usage patterns impact growth in the five assessed Asia-Pacific markets?

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/asthma-therapeutics-in-asiapacific-markets-to-2021-high-prevalence-and-launch-of-latestage-biologics-will-drive-the-market-in-spite-of-affordability-concerns-report.html/toc

Rising asthma prevalence and uptake of newer biologics will lead to significant market growth over the forecast period, in spite of affordability concerns.

- Will affordability threaten the commercial success of existing drugs as well as newer biologics?
- Which of the assessed countries have affordability concerns?

Reasons to buy

This report will enable you to -
- Understand the clinical context of asthma by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
- Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
- Consider market opportunities and potential risks by examining trends in asthma clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in asthma by examining clinical trial data and multi-scenario product forecast projections.
- Compare treatment usage patterns, annual therapy costs, and market growth projections for China, India, Australia, South Korea and Japan.
- Discover trends in licensing and co-development deals concerning asthma products and identify the major strategic consolidations that have shaped the commercial landscape.

Make an Enquiry of this report @ https://www.researchmoz.us/enquiry.php?type=E&repid=686317

Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets Key Trends, Size, Growth, Shares And Forecast Research Report 2023

Researchmoz added Most up-to-date research on "Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" to its huge collection of research reports.

Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012, accounting for 13% of the total number of cancer cases. This figure has been gradually rising with increased smoking and the growing elderly population. Lung cancer is a leading cause of death worldwide, accounting for 1.69 million deaths in 2015. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 a high-risk age range for lung cancer. As the aged population is projected to grow, the prevalence of lung cancer is anticipated to increase, acting as a driver for revenue growth.

The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on different NSCLC subtypes, and the presence of various molecular aberrations.

In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta, while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapies such as Tarceva, Iressa, Gilotrif, Conmana, Xalkori, Alecensa and Zykadia.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1049126

Opdivo and Keytruda are mAbs, immune checkpoint inhibitors targeted towards programmed cell death (PD) 1, and are recent market entrants. The former gained approval for treating advanced or metastatic squamous NSCLC in Japan in 2015 and in Australia and South Korea in 2016, and the latter gained approval in Japan in 2016 for the firstand second-line treatment of patients with PD-L1-positive unresectable advanced/recurrent NSCLC. Tagrisso and Olita EGFR inhibitors that targeted towards EGFR T790M are also recent market entrants, with the former gaining approval in Japan, Australia and South Korea, and the latter approved in South Korea in 2016 for advanced or metastatic patients with EGFR T790M mutation-positive metastatic NSCLC.

There are currently limited options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations. A therapy that targets mutant KRAS abemaciclib is being developed in the pipeline.

Scope

The NSCLC Asia-Pacific market will be valued at $6.2 billion in 2023, growing from $3 billion in 2016 at a CAGR of 10.8%.

- How will immunotherapies such as atezolizumab contribute to growth?
- What effect will patent expirations of currently branded therapies have on market value?
- The NSCLC pipeline is large and diverse, with an increased presence of mAbs and targeted therapies.
- What are the common targets and mechanisms of action of pipeline therapies?
- Will the pipeline address unmet needs such as limited treatment options for squamous cell patients?
- What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?
- Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
- How have the late-stage therapies performed in clinical trials?
- How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
- The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
- How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
- How could changes in risk factors such as population age, smoking habits and pollution influence the market?
- Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion.
- How do deal frequency and value compare between target families and molecule types?
- What were the terms and conditions of key licensing deals?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict NSCLC market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and co-development deals.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1049126

Asthma Therapeutics Market In The Asia-Pacific Region Is Expected To Increase In Value At A Compound Annual Growth Rate (CAGR) Of 7.2%, Over $5.6 Billion

Researchmoz added Most up-to-date research on "Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns" to its huge collection of research reports.

Asthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact causes of asthma are currently unknown, and may be the result of a combination of factors, although two major factors thought to be involved are environmental exposure and host factors, particularly genes.

Asthma treatment can be classed as either a long-term control medication, aimed at controlling persistent asthma, or a quick-relief medication, for the relief of exacerbations and acute symptoms. Long-term control medication includes Inhaled Corticosteroids (ICS), immunomodulators, leukotriene modifiers, cromolyn sodium, nedocromil and methylxanthines. In addition, Long-Acting Beta-Adrenoceptor Agonists (LABAs) can be used in combination with ICSs – but not as monotherapies – for moderate or severe persistent asthma. Currently, only one biologic – Xolair (omalizumab) – is approved as an add-on therapy for the treatment of allergic asthma in the Asia-Pacific region.  Nevertheless, significant unmet need remains for the treatment of severe eosinophilic asthma.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=686317

Scope

The current asthma market in the Asia-Pacific region contains novel products, including Xolair, a recombinant humanized monoclonal anti-IgE antibody; Seretide/Adoair, an ICS-LABA combination therapy; Relvar/Breo, an ICS-LABA combination therapy, and Spiriva, a LAMA.

- What are the competitive advantages of the existing novel drugs?

With over 274 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, with improved dosing regimens and administration routes in comparison to currently marketed products.

- Which classes of novel drugs are most prominent within the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the asthma market – specifically for severe eosinophilic asthma?

Analysis of clinical trials since 2006 has identified that the failure rates of asthma molecules were highest in Phase III (46%), with the overall attrition rate for asthma in development being 78%.

- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?

Over the 2014–2021 forecast period, the asthma therapeutics market in the Asia-Pacific region is expected to increase in value at a Compound Annual Growth Rate (CAGR) of 7.2%, from $3.5 billion to over $5.6 billion.

- Which markets make the most significant contribution to the current market size?
- What are the epidemiology trends in these markets?
- Will new market entrants lead to substantial changes in annual therapy costs?
- How will different treatment usage patterns impact growth in the five assessed Asia-Pacific markets?

Rising asthma prevalence and uptake of newer biologics will lead to significant market growth over the forecast period, in spite of affordability concerns.

- Will affordability threaten the commercial success of existing drugs as well as newer biologics?
- Which of the assessed countries have affordability concerns?

Reasons to buy

This report will enable you to -
- Understand the clinical context of asthma by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
- Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
- Consider market opportunities and potential risks by examining trends in asthma clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in asthma by examining clinical trial data and multi-scenario product forecast projections.
- Compare treatment usage patterns, annual therapy costs, and market growth projections for China, India, Australia, South Korea and Japan.
- Discover trends in licensing and co-development deals concerning asthma products and identify the major strategic consolidations that have shaped the commercial landscape.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=686317

Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets Research Report 2022 | Researchmoz.us

Researchmoz added Most up-to-date research on "Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2022 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" to its huge collection of research reports.

Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012 globally, accounting for 13% of the total number of cancer cases. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 - a high-risk age range for lung cancer. As the aged population is projected to increase, the prevalence of lung cancer is anticipated to increase, thereby acting as a driver for revenue growth. The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a gradual change from a focus on generic chemotherapy regimens to a complex treatment landscape based on different NSCLC subtypes, and the presence of various molecular aberrations.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=725317

In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta (pemetrexed), while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapies such as Tarceva, Iressa, Xalkori and Gilotrif. Opdivo (nivolumab) - a mAb immune checkpoint inhibitor targeted towards Programmed cell Death (PD) 1 - is a recent market entrant, gaining approval for treating advanced or metastatic squamous NSCLC patients in Japan in 2015 and in Australia in 2016. While the NSCLC developmental pipeline must aim to improve the outlook for all patients, there is currently a lack of options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations. Therapies that target mutant T790M and KRAS are being developed in the pipeline, with osimertinib, targeting T790M, gaining approval in Japan in 2016.

Scope

The NSCLC Asia-Pacific market will be valued at $4.9 billion in 2022, growing from $2.7 billion in 2015 at a CAGR of 8.7%.

- How will immunotherapies such as Keytruda contribute to the growth?
- What effect will patent expirations of currently branded therapies have on market value?

The NSCLC pipeline is large and diverse, with an increased presence of mAbs and targeted therapies.

- What are the common targets and mechanisms of action of pipeline therapies?
- Will the pipeline address unmet needs such as a lack of treatments for squamous cell patients?
- What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

- How have the late-stage therapies performed in clinical trials?
- How would the approval of rociletinib to treat T790M mutant patients affect the competitive landscape, with its competitor osimertinib (AZD-9291) already approved in Japan in 2016?
- How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.

-   How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
-   How could changes in risk factors such as population age, smoking habits and pollution influence the market?

Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion.

-   How do deal frequency and value compare between target families and molecule types?
-   What were the terms and conditions of key licensing deals?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict NSCLC market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and co-development deals.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=725317

Osteoporosis Therapeutics in Asia-Pacific Markets Key Trends, Size, Growth, Shares And Forecast Research Report 2022

Researchmoz added Most up-to-date research on "Osteoporosis Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Anabolic Therapies" to its huge collection of research reports.

Osteoporosis, the most common metabolic bone disease, is characterized by low bone mass, microarchitectural deterioration of bone tissue, and a consequent increase in fracture risk. Osteoporosis is generally known as an asymptomatic disease, as there are no visible signs until a fracture occur. In most of the cases, fracture is the clinical outcome associated with osteoporosis, and it has a complex pathogenesis that involves trauma to the bone and increased skeletal fragility. Osteoporosis is a major global public health problem, associated with significant morbidity, mortality, and socioeconomic burden. An aging global population will result in an increased number of people living with the condition, thereby acting as a driver for revenue growth.

The osteoporosis market is undergoing a gradual transition from a focus on antiresorptive therapies to anabolic drug treatment. The market is set to be driven by recently launched products, and the approval of drugs that will supplement current market leaders and offer greater therapeutic options. The marketed products landscape comprises a wide range of treatment options, including bisphosphonates, SERMs, RANKL inhibitors, a dual-action non-bisphosphonate (strontium ranelate), calcitonins and PTH analogues. Nevertheless, significant unmet need remains for products that can improve bone formation, as well as effective antiresorptive therapies that offer increased compliance with few side effects.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=784620

Scope

The osteoporosis Asia-Pacific market will be valued at $7.7 billion in 2022, growing from $4.5 billion in 2015 at a CAGR of 7.8%.

- Bisphosphonates and SERMs dominate the osteoporosis market. However, unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs of the osteoporosis market?
- How will immunotherapies such as Prolia contribute to growth?
- What effect will the patent expirations of currently branded therapies have on market value?

The pipeline contains a range of molecule types and molecular targets, including those that are well established in osteoporosis, and novel, first-in-class therapies.

- Which molecular targets appear most frequently in the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the osteoporosis market?
- Will the pipeline address unmet needs related to limited anabolic therapies for osteoporosis patients?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the emergence of novel therapies.

- How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
- How could changes in risk factors such as aging population, calcium and vitamin D deficiency influence the market?
- Various drivers and barriers will influence the market over the forecast period.
- What are the barriers that limit the uptake of premium-priced therapeutics in the assessed countries?
- Which factors are most likely to drive the market in these countries?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the osteoporosis market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the osteoporosis pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, - and how they will compete with other therapies.
- Predict osteoporosis market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the osteoporosis deals landscape by analyzing trends in licensing and co-development deals.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=784620

Asia-Pacific Myeloma Therapeutics Industry Key Trends, Size, Growth, Shares And Forecast Research Report 2021

Researchmoz added Most up-to-date research on "Myeloma Therapeutics in Asia-Pacific Markets to 2021 – Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments" to its huge collection of research reports.

Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. The disease is incurable; although over the past decade there have been significant improvements in therapy, driven by a greater understanding of pathophysiology. MM represents about 0.8–1% of all cancer cases worldwide and approximately 10% of all hematological cancers, with incidence rates ranging from 0.4 to 5 per 100,000 persons in different parts of the world.

Without any treatment, the median survival of a myeloma patient is about six months, but this can be extended with the use of various forms of treatment. There are now five classes of drugs used in the treatment of myeloma: immunomodulatory drugs, chemotherapy, proteasome drugs, Histone Deacetylase (HDAC) inhibitors and steroids. Many of the notable drugs in these classes were approved over the past 10–15 years. Treatment using these novel drugs and high-dose chemotherapy with hematopoietic Stem-Cell Transplant (SCT) has been shown to improve median survival to five years, which makes this the current standard therapy. However, many patients suffer relapse or develop treatment resistance, leaving a need to develop safe and effective treatments that prolong the duration of remission and improve survival.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=399076

Scope

The different  segments of patients with MM are based on their eligibility for an SCT
- What combination therapies are used for various segments?
- What are the treatment options available for myeloma, providing an overview of the front-line, second-line and third-line therapies available?
There are seven main marketed products for MM, with most of the novel drugs being approved in the last decade.
- What are the dominant mechanisms of action across marketed products?
- Which products are approved currently in each country and which ones are likely to be launched within the forecast period?
- Which product is used more in each country?
- Will there be any label expansions of existing market leaders in any of the countries?
Epidemiology of MM is significantly different in Asia-Pacific countries from that in the major markets.
- What are the various epidemiology trends in each country?
- What factors contribute to the overall epidemiology?
The MM pipeline consists of more than 250 products in active development. Small molecules are the most abundant molecule type in the pipeline, accounting for 48% of all products.
- What are the various pipeline products based on molecule type, mechanism of action and stage of development?
- Which class is most prominent within the pipeline?
- Do the pipeline molecules offer an advantage over commercially proven mechanisms?
- What are the late-pipeline products expected to be launched in each country in the near future?
Analysis of clinical trials since 2006 identified that MM products have a high rate of attrition.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?
- What are the current promising pipeline drugs and their efficacy data?
Over the 2014–2020 forecast period, the MM market in Australia, China, India and Japan is expected to increase in value at a CAGR of 7.4%, from $1.7 billion to about $2.8 billion.
- Which markets make the most significant contribution to the current market size?
- What are the incidence, diagnosis and treatment trends in these markets?
- What are the factors responsible for difference in the treatment patterns within the four markets?
- Which factors will influence growth rates?
- Will new market entrants lead to substantial changes in annual therapy costs?
Some key marketed products are expected to expire in the forecast period, and promising pipeline molecules are likely to be launched in the near future.
- Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?
- Will the patent expiration be offset by the approval of new therapies?

Reasons to buy

This report will enable you to -
- Understand the clinical context of MM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
- Appreciate key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
- Consider market opportunities and potential risks by examining trends in clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential by examining clinical trial data and multi-scenario product forecast projections.
- Compare treatment usage patterns, annual therapy costs, and market growth projections for India, China, Australia and Japan.
- Discover trends in licensing and co-development deals concerning MM products and identify the major strategic consolidations that have shaped the commercial landscape.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=399076

Asia-Pacific Psoriasis Therapeutics Markets Advent of Novel Biologics 2021 | New Study

Researchmoz added Most up-to-date research on "Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth" to its huge collection of research reports.

GBI Research, the leading business intelligence provider, has released its latest research, ""Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth"", which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Research’s team of industry experts.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=285644

In 2014, the value of the psoriasis therapeutics market in APAC amounted to an estimated $690m, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.4% between 2014 and 2021 to reach $1.2 billion. The psoriasis treatment landscape is a particularly complex one. More than 80% of patients fall into the mild-or-moderate category, for which the first line of treatment is topical drugs, phototherapy, or a combination. In the case of severe patients, non-steroidal drugs such as methotrexate, cyclosporine, and acitretin are practiced as first-line treatment; however, they come with toxicity concerns and so cannot be prescribed for long durations. Biologics such as TNF inhibitors (adalimumab, etanercept, infliximab) and ustekinumab are largely prescribed as second-line therapy when none of the aforementioned options provide the desired results. However, during the forecast period, biologics are likely gain a significant patient share due to healthcare plans in APAC and awareness regarding the effectiveness of biologics. Among the recently launched biologics, Cosentyx (secukinumab) from Novartis has shown better efficacy than Enbrel (etanercept), and is a novel molecule that targets Interluekin-17 (IL-7). Biocon India has launched Alzumab (itolizumab), which is a first-in-class novel molecule that targets CD6 protein. It is anticipated to be the leading biologic in India by the end of forecast period. Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab) are expected to lose their patent during the forecast period, but will be compensated for by biosimilar versions.

Scope

- The report analyzes treatment use patterns, market characterization, the pipeline, and key licensing and co-development deals for psoriasis in the APAC markets of China, India, Japan, and Australia.The report includes
- A brief introduction to psoriasis, including pathophysiology, etiology, diagnosis, and treatment algorithms
- In-depth analysis of currently marketed drugs, including analysis of safety, efficacy, treatment patterns, and strengths/weaknesses, along with a heat map comparing them in terms of safety and efficacy
- A comprehensive review of the pipeline for psoriasis, including individual analysis of a number of late-stage pipeline drugs likely to enter the market during the forecast period; the pipeline is further analyzed on the basis of phase distribution, molecule type, program type, mechanism of action, and molecular target
- Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration, and program failure rate for each molecule type
- Multi-scenario forecast data for the market to 2021, taking into account how it might be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets
- Discussion of the drivers of and barriers to market growth
- In-depth analysis of all licensing and co-development deals that have occurred in the psoriasis market since 2006

Reasons to buy

The report will enhance your decision-making capability by allowing you to
- Understand the psoriasis pipeline and the factors that indicate that it is becoming more innovative
- Analyze detailed profiles for promising pipeline products and gain insights into how they are likely to compete in the market and who their main competitors will be
- Follow the trends in psoriasis clinical trial size and duration in relation to industry averages
- Assess the potential risk of future developmental programs for psoriasis therapeutics by mechanism of action using recorded clinical trial failure rates
- Analyze the potential growth patterns expected for the psoriasis market over the forecast period
- Identify the countries that are expected to contribute the most to this growth and devise a more effectively tailored country strategy through an understanding of key drivers and barriers
- Accelerate and strengthen your market position by identifying key companies for strategic partnerships

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=285644

The Hemophilia A and B Asia-Pacific market will be valued at $699.1m and $112.9m respectively in 2022, growing from $444.9m and $76.3m in 2015, at CAGR of 6.7% and 5.8%

Researchmoz added Most up-to-date research on "Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy" to its huge collection of research reports.

Hemophilia is a rare disease affecting more than 400,000 people worldwide. Hemophilia A is four times as common as hemophilia B, and more than half of patients with hemophilia A have a severe form of hemophilia. Males have a much higher chance of developing hemophilia because they only receive one copy of the X chromosome from their mother.

The mainstay of treatment for hemophilia is to replace the missing factor VIII or factor IX, produced using plasma-derived or recombinant methods. Some patients develop inhibitors to factor VIII or factor IX treatment and need a bypassing agent, such as factor VIIa, to resolve bleeds. Patients of hemophilia A or B often require lifelong treatment to prevent and control bleeding episodes, and this therefore represents a lucrative market opportunity.

The current marketed products landscape comprises replacement factor therapies, such as recombinant therapies and new long-acting recombinant products. The current pipeline shows strong promise, as it shows a gradual shift from short-acting recombinant factor VIII or factor IX to long-acting recombinant factor VIII, and from factor replacement therapies to non-factor therapies. Nevertheless, significant unmet need remains for products that can avoid the development of inhibitors in patients with hemophilia.

Though late-stage pipeline for treatment of hemophilia seems promising, the main market restraint is likely to be low penetration of new long-acting recombinant therapies in India and China, owing to their high expected prices.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=879379

Scope

- The Hemophilia A and B Asia-Pacific market will be valued at $699.1m and $112.9m respectively in 2022, growing from $444.9m and $76.3m in 2015, at compound annual growth rates of 6.7% and 5.8%.
- How will non-factor therapies contribute to the growth?
- What will be the impact of the new long-acting recombinant factor VIII and recombinant factor IX products in the hemophilia A and B market sales?
- The pipeline contains a range of molecule types and molecular targets, including both those that are well established in hemophilia A and B, and novel targeted therapies.
- Which molecular targets appear most frequently in the pipeline?
- Will the pipeline address unmet needs such as less frequently administered therapies and risk of inhibitor development for hemophilia A and B patients?
- What are the most promising first-in-class targets for hemophilia A and B?
- Will the current first-in-class targets have a broader therapeutic potential across the Asia-Pacific markets?
- Various drivers and barriers will influence the market over the forecast period.
- What are the barriers that will limit the uptake of premium-priced recombinant factor VIII and recombinant factor IX therapies in the assessed countries?
- Which factors are most likely to drive the market in these countries?
- Co-development deals are the most common form of strategic alliance in hemophilia A and B, with total deal values ranging from under $10m to over $280m.
- How do deal frequency and value compare between target families and molecule types?
- What were the terms and conditions of key co-development deals?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the hemophilia A and B market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the hemophilia A and B pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches to treating hemophilia A and B.
- Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict hemophilia A and B market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the hemophilia A and B deals landscape by analyzing trends in licensing and co-development deals.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=879379